Spain Cardiovascular Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The spain cardiovascular devices market size was valued at USD 1.55 billion in 2025 and estimated to grow from USD 1.63 billion in 2026 to reach USD 2.09 billion by 2031, at a CAGR of 5.08% during the forecast period (2026-2031). This report is Segmented by Device Type (Diagnostic & Monitoring Devices, Therapeutic & Surgical Devices), Indication (Coronary Artery Disease, Arrhythmia, Heart Failure, Valvular Heart Disease), End User (Hospitals, Home Care Settings, Others), and Geography (Spain). The Market Forecasts are Provided in Terms of Value (USD).

Spain Cardiovascular Devices Market Trends and Insights

National Cardiovascular Health Plan 2022-2029 Catalyzing Public Procurement

The plan allocates EUR 215 million for cardiovascular equipment modernization, accelerating replacement of aging imaging systems and catheterization labs. Standardized multi-year service contracts shorten bid cycles and guarantee training, which spurs volume-led growth for basic diagnostic platforms and value-driven demand for advanced technologies. Hospitals in underserved regions gain faster access to updated cardiac ultrasound, while flagship centers adopt fully integrated cath-lab suites. Suppliers with tiered portfolios capture share by meeting both ends of the performance spectrum.

Rapidly Ageing Population Expanding Device Demand

Citizens older than 65 generate a disproportionate share of cardiac procedures, and their clustering along the Mediterranean coastline creates utilization hotspots. Octogenarians are now the fastest-growing group for transcatheter valve replacement, prompting hospitals to revise scheduling and after-care protocols. Manufacturers have answered with smaller implants and longer battery life, which reduce rehospitalization risk. Hospitals that embrace geriatric-friendly technology often see utilization efficiencies that exceed regional averages.

Regional Tender Price Caps Compress Selling Prices

Autonomous communities such as Andalusia and Valencia enforce reference pricing 15-20% below direct-negotiation levels. The model prioritizes total cost of ownership, encouraging bids that bundle disposables, maintenance, and training. Mid-tier suppliers leave low-margin categories, consolidating share among firms that leverage scale. Hospitals could face fewer options in commodity segments if the current rules persist.

Other drivers and restraints analyzed in the detailed report include:

• Reimbursement of TAVR & TMVR Accelerating Structural Heart Uptake
• Expansion of Private Cardiology Networks Driving Premium Equipment
• MDR Recertification Backlog Delaying Product Launches

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Therapeutic and surgical devices held 56.78% of Spain cardiovascular devices market share in 2025, buoyed by coronary stents and cardiac rhythm-management implants. Concurrently, the Spain cardiovascular devices market size for diagnostic and monitoring equipment is expected to grow at 5.86% CAGR through 2031 thanks to AI-guided imaging and national funding for early detection. Advanced transcatheter tools also shorten the life cycle of older surgical devices, shifting procurement toward minimally invasive systems that shorten hospital stays. Vendors that can package modular software licenses with core hardware capture incremental revenue without proportionally higher production costs.

Diagnostic adoption is no longer confined to academic centers. Fractional flow-reserve platforms and 3D echocardiography are penetrating regional hospitals, encouraged by standardized procurement guidelines under the National Cardiovascular Health Plan. At the same time, the therapeutic segment is intensifying its focus on structural heart interventions as payers recognize the cost benefits of shorter recovery times. Hospitals that achieve lower length-of-stay metrics through device innovation often qualify for performance-based financing, bolstering demand for the latest implants.

Complete Report Scope:

• By Device
  • Diagnostic & Monitoring Devices
    • ECG Systems
    • Remote Cardiac Monitor
    • Cardiac MRI
    • Cardiac CT
    • Echocardiography / Ultrasound
    • Fractional Flow Reserve (FFR) Systems
  • Therapeutic & Surgical Devices
    • Coronary Stents
      • Drug-Eluting Stents
      • Bare-Metal Stents
      • Bioresorbable Stents
    • Catheters
      • PTCA Balloon Catheters
      • IVUS/OCT Catheters
    • Cardiac Rhythm Management
      • Pacemakers
      • Implantable Cardioverter Defibrillators
      • Cardiac Resynchronization Therapy Devices
    • Heart Valves
      • TAVR/TAVI
      • Mechanical Valves
      • Tissue/Bioprosthetic Valves
    • Ventricular Assist Devices
    • Artificial Hearts
    • Grafts & Patches
    • Other Cardiovascular Surgical Devices
• By Indication
  • Coronary Artery Disease
  • Arrhythmia
  • Heart Failure
  • Valvular Heart Disease
• By End User
  • Hospitals
  • Home Care Settings
  • Others

List of Companies Covered in this Report:

• Medtronic
• Boston Scientific
• Abbott Laboratories
• Edward Lifesciences
• Koninklijke Philips
• Siemens Healthineers
• Terumo
• BIOTRONIK
• MicroPort
• LivaNova
• Cardinal Health
• B. Braun
• Meril Life Science
• Acist Medical Systems
• Getinge AB (Maquet)
• W. L. Gore & Associates
• Johnson & Johnson
• Teleflex

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support